Wixela Inhub vs. Breo Ellipta

• Are Wixela Inhub and Breo Ellipta the Same Thing?
• What Are Possible Side Effects of Wixela Inhub?
• What Are Possible Side Effects of Breo Ellipta?
• What Is Wixela Inhub?
• What Is Breo Ellipta?
• What Drugs Interact with Wixela Inhub?
• What Drugs Interact with Breo Ellipta?
• How Should Wixela Inhub Be Taken?
• How Should Breo Ellipta Be Taken?

Wixela Inhub (fluticasone propionate and salmeterol inhalation powder) and Breo Ellipta (fluticasone furoate and vilanterol) are combinations of a corticosteroid and a long-acting beta-adrenergic agonist (LABA) used to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Wixela Inhub is also used for twice-daily treatment of asthma in patients aged 4 years and older.

Breo Ellipta is also used to reduce exacerbations (sudden worsening) of COPD in patients with a history of exacerbations.

Side effects of Wixela Inhub and Breo Ellipta that are similar include upper respiratory tract infection or inflammation, sore throat, oral candidiasis (thrush in your mouth or throat), bronchitis, cough, headaches, and pneumonia.

Side effects of Wixela Inhub that are different from Breo Ellipta include hoarseness, nausea, vomiting, and musculoskeletal pain.

Side effects of Breo Ellipta that are different from Wixela Inhub include runny nose, back pain, sinus infection, mouth pain, joint pain, influenza, sore throat, and fever.

Both Wixela Inhub and Breo Ellipta may interact with azole antifungals, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, and diuretics.

Wixela Inhub may also interact with other medicines containing a LABA, antivirals, clarithromycin, telithromycin, and nefazodone.

Common side effects of Wixela Inhub include:

• upper respiratory tract infection or inflammation,
• sore throat,
• hoarseness,
• oral thrush,
• bronchitis,
• cough,
• headaches,
• nausea and vomiting,
• pneumonia,
• viral respiratory infections, and
• musculoskeletal pain

Common side effects of Breo Ellipta include:

• upper respiratory tract infection,
• runny nose,
• sore throat,
• headache,
• oral candidiasis (thrush in your mouth or throat),
• back pain,
• pneumonia,
• bronchitis,
• sinus infection,
• cough,
• mouth pain,
• joint pain,
• influenza,
• sore throat, and
• fever.

Wixela Inhub (fluticasone propionate and salmeterol inhalation powder) contains a combination of a corticosteroid and a long-acting beta-adrenergic agonist (LABA) indicated for twice-daily treatment of asthma in patients aged 4 years and older or maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). Wixela Inhub is available in generic form.

Breo Ellipta combines an inhaled corticosteroid (ICS) medicine, fluticasone furoate, and a LABA medicine, vilanterol.

ICS medicines such as fluticasone furoate help to decrease inflammation in the lungs. Inflammation in the lungs can lead to breathing problems.

LABA medicines such as vilanterol help the muscles around the airways in your lungs stay relaxed to prevent symptoms, such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe.

Breo Ellipta should not be used in children and adolescents. It is not known if Breo Ellipta is safe and effective in children and adolescents younger than 18 years of age.

Breo Ellipta is used for COPD and asthma and as follows:

• Breo Ellipta 100/25 is a prescription medicine used to treat COPD. COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both. Breo Ellipta 100/25 is used long term as 1 inhalation 1 time each day to improve symptoms of COPD for better breathing and to reduce the number of flare-ups (the worsening of your COPD symptoms for several days).
• Breo Ellipta is not used to relieve sudden breathing problems and will not replace a rescue inhaler.
• Breo Ellipta is a prescription medicine used as 1 inhalation 1 time each day to prevent and control symptoms of asthma for better breathing and to prevent symptoms such as wheezing.
• Breo Ellipta contains vilanterol. LABA medicines such as vilanterol increase the risk of death from asthma problems.
• Breo Ellipta is not for people with asthma who are well controlled with an asthma control medicine, such as a low to medium dose of an inhaled corticosteroid medicine.
• Breo Ellipta is not used to relieve sudden breathing problems and will not replace a rescue inhaler.

Wixela Inhub may interact with additional medicines containing a LABA, ritonavir, ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, and diuretics. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Wixela Inhub; it is unknown how it would affect a fetus. It is unknown if Wixela Inhub passes into breast milk. Consult your doctor before breastfeeding.

Breo Ellipta may interact with antifungal medications containing ketoconazole, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, or diuretics.

The dose of Wixela Inhub for treatment of asthma in patients aged 12 years and older is 1 inhalation of Wixela Inhub 100/50, Wixela Inhub 250/50, or Wixela Inhub 500/50 twice daily. The dose of Wixela Inhub for treatment of asthma in patients aged 4 to 11 years is 1 inhalation of Wixela Inhub 100/50 twice daily. The dose of Wixela Inhub for maintenance treatment of COPD is 1 inhalation of Wixela Inhub 250/50 twice daily.

Breo Ellipta is dosed as 100 mcg/25 mcg once daily. Breo Ellipta is a dry powder for oral inhalation only. Patients with allergies to milk or milk proteins and patients with sensitivities to any component of Breo Ellipta should not use it.